30,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company's stock, valued at approximately $821,000. Walleye Capital LLC owned about 0.10% of Dianthus Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. MetLife Investment Management LLC lifted its holdings in Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company's stock worth $382,000 after acquiring an additional 7,854 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock worth $4,543,000 after acquiring an additional 97,362 shares during the last quarter. Quest Partners LLC lifted its holdings in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after acquiring an additional 4,506 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Dianthus Therapeutics in the second quarter valued at approximately $236,000. Institutional investors own 47.53% of the company's stock.

Analysts Set New Price Targets

DNTH has been the topic of several analyst reports. Raymond James raised their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a research note on Friday, November 8th. Oppenheimer raised their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. Wedbush dropped their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $0.73 during mid-day trading on Friday, reaching $24.39. 167,938 shares of the company traded hands, compared to its average volume of 341,741. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm has a market cap of $721.94 million, a PE ratio of -9.76 and a beta of 1.74. The stock has a fifty day simple moving average of $26.44 and a 200-day simple moving average of $26.51.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.